AMDX-2011P
Phase 2Small molecule
AMDX-2011P is one of 120 small molecule programs targeting Alzheimer disease. It is currently in Phase 2.
3
Indications
3
Total Trials
3
Active Trials
119
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
100 competitors in Alzheimer Disease
#DrugCompanyPhaseTrials
1Niacor
AbbVieApproved
Neupro
UCBApproved
Lexapro
AbbVieApproved
Calciferol
Jazz PharmaceuticalsApproved
Evista
Eli LillyApproved
Azilect
TevaApproved
Celebrex
PPhiladelphia Eye Associates
Approved
Kisunla
Eli LillyPhase 3
Rexulti
OtsukaApproved
Rilutek
AAzurity Pharmaceuticals
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AMDX-2011P. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAmydis Inc.